Clinical Trial Update: A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

A Phase II neoadjuvant trial evaluating sacituzumab govitecan plus pembrolizumab in immunochemotherapy-resistant, early-stage triple-negative breast cancer; sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)
• Sacituzumab Govitecan (Trodelvy) (sacituzumab govitecan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING